Lupin receives approval from USFDA for Penicillamine Tablets USP


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Lupin receives approval from USFDA for Penicillamine Tablets USP
Penicillamine Tablets USP, 250 mg, are indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis

Pharma major Lupin Limited announced that it has received approval for its Penicillamine Tablets USP, 250 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Depen Tablets, 250 mg, of Mylan Specialty, L.P. The product would be manufactured at Lupin’s Nagpur facility and is expected to be launched shortly.

Penicillamine Tablets USP, 250 mg, are indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.

Penicillamine Tablets USP (RLD: Depen) had an annual sales of approximately USD 4 million in the U.S. (IQVIA MAT September 2020).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the 3rd largest pharmaceutical company in the U.S. by prescriptions and 5th in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Tags : #LupinLimited #LatestNewsonLupinLimited1stNov #LatestUSFDAApproval1stDec #LatestPharmaNews1stDec #RheumatoidArthritis

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Beyond Romance: The Medical Nightmare Called Broken Heart SyndromeMay 19, 2025
⁠ How to Track Your Cardiovascular Health at HomeMay 19, 2025
Cholesterol and PCOS: The Hidden ConnectionMay 19, 2025
Why Younger Women Are Getting HypertensionMay 19, 2025
⁠Thyroid Disorders in Women: Symptoms Doctors Want You to KnowMay 19, 2025
Why Your Grocery List May Be the Best Prescription for HypertensionMay 19, 2025
Heart Disease Isn’t Just a Man’s Problem: Signs Women MissMay 19, 2025
Two Genders, Two Heartbeats: The Genetic Divide No One Saw ComingMay 19, 2025
GestureX: Chandigarh Students secure Govt Patent for Smart Glasses That Convert Speech to Sign LanguageMay 19, 2025
Asian Hospital, Faridabad Becomes the First in the City to Launch Total Lab Automation with QuidelOrthoMay 19, 2025
Why Maternal Health May Be Entering Its Most Dangerous Era YetMay 17, 2025
The Cancer-Fighting Habit That Costs Nothing but Changes EverythingMay 17, 2025
When Fitness Turns Into a Fight: Can Too Much Exercise Hurt a Teen’s Mind?May 17, 2025
CARE Hospitals Hosts National Ultrasound Life Support (NULS) Workshop in Association with SEMI —A Landmark in Collaborative Medical EducationMay 17, 2025
Olive Hospital Marks World Hypertension Day with a Call for Regular Blood Pressure MonitoringMay 17, 2025
Hypertension in India: A Silent EpidemicMay 16, 2025
Know Your Blood Pressure & Keep It Under CheckMay 16, 2025
SBI Securities Contributed ₹49 Lakh to Enhance Eye Care Services in Odisha and West Bengal.May 16, 2025
7 Must Have Apps to Help You Break Free and Redefine Your Daily RoutineMay 16, 2025
Çelebi Aviation India Refutes False Allegations; Reaffirms Its Long-standing Commitment to India’s Aviation SectorMay 16, 2025